bpc-157 clinical evidence randomized trial humans as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers Stable Gastric Pentadecapeptide BPC 157
Description
In individuals with symptomatic B 12 deficiency despite normal dietary B 12 intake, B 12 malabsorption is the most likely cause and should guide parenteral therapy
Pure Canada Peptides supplies BPC-157 + TB-500 Blend (5 mg / 5 mg), lyophilized and tested in Canada
Cytometry B Clin Cytom
Some of these peptides remain experimental and unregulated, with little scientific evidence for their benefits in humans
For unapproved compounds like these peptides, the judicial picture is even less settled
